Istaroxime was added to currently available inotropes and vasopressors in the study - no new safety signals were identified and physiological improvements were consistent with istaroxime responses in ...

Sarilumab and tocilizumab are equally effective in reducing organ support duration and death in patients who are critically ill with COVID-19.

Updated daily, the FDA calendar gives you insight into FDA actions on companies and upcoming actions the FDA is expected to take. Benzinga's FDA calendar shows historical FDA data, upcoming dates ...

WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has reported encouraging interim results from its ongoing ...

Current treatments for systolic heart failure, which aim to improve heart contractility and cardiac output, face several challenges. Many therapies, such as inotropes, temporarily boost contractility ...